MedTrace Logo

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

NCT07204457 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1123

Last updated 2025-12-01

No results posted yet for this study

Summary

Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

Conditions

  • Meningococcal Infections

Interventions

BIOLOGICAL

EG-MCV4

single intramuscular dose on Day 0

BIOLOGICAL

Menveo

single intramuscular dose on Day 0

Sponsors & Collaborators

  • BMI Korea

    collaborator INDUSTRY

  • EyeGene Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2026-09-30
Completion
2027-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07204457 on ClinicalTrials.gov